文献速递心力衰竭与心肌病心律失常

心力衰竭患者生物标志物谱比较:房颤与窦性心律及射血分数降低与保留的差异

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
PubMed 文献 · Eur Heart J · 2018-01-01

该研究基于BIOSTAT-CHF观察性队列,回顾性分析2152例HFrEF患者(1419例窦性心律,733例房颤)和524例HFpEF患者(286例窦性心律,238例房颤),测量92种心血管风险标志物。结果显示HFrEF中房颤与84%标志物升高相关,而HFpEF中窦性心律升高标志物更多;中位随访21个月,房颤与死亡风险增加相关(多变量HR 1.27,95%CI 1.09-1.48,P=0.002),心律与EF组间无显著交互作用。

要点

  • HFrEF合并房颤患者呈现均匀升高的心血管风险标志物谱。
  • HFpEF合并房颤患者风险标志物谱较为分散,提示病理机制不同。
  • 房颤与全因死亡风险增加独立相关,且不受EF分组影响。

核心结论

  • 在HFrEF患者中,房颤与均匀升高的心血管风险标志物谱相关;在HFpEF患者中,房颤与更分散的风险标志物谱相关,提示两种心衰表型中房颤的病理生理机制存在差异。
  • 房颤与增加的全因死亡风险独立相关(多变量HR 1.27,95%CI 1.09-1.48,P=0.002),且心律与EF组间对结局无显著交互作用。

研究设计与样本

  • 研究为BIOSTAT-CHF观察性队列的回顾性分析,纳入2152例HFrEF患者(EF<40%,其中1419例窦性心律、733例房颤)和524例HFpEF患者(EF≥50%,其中286例窦性心律、238例房颤)。
  • 使用Proseek® Olink Cardiovascular III panel测量92种心血管风险标志物。

主要发现

  • 在HFrEF中,房颤与92种标志物中77种(84%)水平较窦性心律升高相关。
  • 在HFpEF中,更多标志物在窦性心律中高于房颤。
  • 中位随访21个月,房颤与死亡风险增加相关(多变量HR 1.27,95%CI 1.09-1.48,P=0.002)。
  • 心律与EF组间对结局无显著交互作用。

临床怎么用

  • 对于HFrEF合并房颤的患者,应关注其普遍升高的心血管风险标志物谱,可能提示更高的风险负担。
  • 对于HFpEF合并房颤的患者,风险标志物谱分散,需个体化评估,不宜简单类推HFrEF的机制。
  • 房颤的存在与死亡风险增加独立相关,在心力衰竭管理中应重视房颤的评估与处理。

局限性

  • 研究为回顾性观察性分析,可能存在残余混杂。
  • 生物标志物测量基于特定panel,未涵盖所有潜在通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The clinical correlates and consequences of atrial fibrillation (AF) might be different between heart failure with reduced vs. preserved ejection fraction (HFrEF vs. HFpEF). Biomarkers may provide insights into underlying pathophysiological mechanisms of AF in these different heart failure (HF) phenotypes. METHODS AND RESULTS: We performed a retrospective analysis of the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which was an observational cohort. We studied 2152 patients with HFrEF [ejection fraction (EF < 40%)], of which 1419 were in sinus rhythm (SR) and 733 had AF. Another 524 patients with HFpEF (EF ≥50%) were studied, of which 286 in SR and 238 with AF. For the comparison of biomarker profiles, 92 cardiovascular risk markers were measured (Proseek® Olink Cardiovascular III panel). The circulating risk marker pattern observed in HFrEF was different than the pattern in HFpEF: in HFrEF, AF was associated with higher levels of 77 of 92 (84%) risk markers compared to SR; whereas in HFpEF, many more markers were higher in SR than in AF. Over a median follow-up of 21 months, AF was associated with increased mortality risk [multivariable hazard ratio (HR) of 1.27; 95% confidence interval (CI) 1.09-1.48, P = 0.002]; there was no significant interaction between heart rhythm and EF group on outcome. CONCLUSION: In patients with HFrEF, the presence of AF was associated with a homogeneously elevated cardiovascular risk marker profile. In contrast, in patients with HFpEF, the presence of AF was associated with a more scattered risk marker profile, suggesting differences in underlying pathophysiological mechanisms of AF in these HF phenotypes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Santema BT, Kloosterman M, Van Gelder IC, et al. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J. 2018. PMID: 30137304. doi:10.1093/eurheartj/ehy421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。